GSK plc
Search results
2 days ago · The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19.
Jun 25, 2024 · Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant ...
Jul 2, 2024 · Professor Sarah Gilbert describes the process. The story behind the first successful clinical trial results showing the vaccine was effective, released in November 2020, started back in January that year. This was when we first heard reports of a new respiratory disease emerging in China.
Jul 14, 2024 · AstraZeneca, British-Swedish biopharmaceutical company with medicine sales in more than 130 countries, making it one of the largest drug companies in the world. AstraZeneca’s main research and development areas include oncology, rare diseases, and biopharmaceutical intervention, and it has numerous.
Jun 25, 2024 · ADJUVANT BR.31 is a randomised, multi-centre, double-blind Phase III trial sponsored by CCTG evaluating Imfinzi in the adjuvant treatment of 1,415 patients with Stage IB (≥4cm), II or IIIA (Seventh Edition AJCC Cancer Staging Manual) NSCLC following complete tumour resection with or without adjuvant chemotherapy.
4 days ago · Building on the Ministry of Health's previous COVIDNOW dashboard, this page provides a summarised view of the COVID-19 vaccination program in Malaysia, allowing you to track its evolution on a daily basis.
Jun 27, 2024 · While some vaccine makers used newer approaches to fight COVID-19, others turned to more established methods. The pharmaceutical company AstraZeneca partnered with Oxford University to develop an adenovirus-based vaccine, officially named ChAdOx1 nCoV-19 (AZD1222). The vaccine is a viral vector vaccine.
